**Merck and Moderna maintain a decade-old 50/50 partnership on their personalized mRNA cancer vaccine (intismeran autogene/V940) rather than pursuing a full merger or acquisition.** Positive Phase 3 melanoma data announced in mid-August 2026, showing reduced recurrence and metastasis risk versus Keytruda alone, has driven sharp share-price gains—Moderna roughly doubling and Merck rising over 10%—while reinforcing the collaborative structure that splits costs and profits without ownership change. Merck’s recent deal activity, including the $6.7 billion Terns Pharmaceuticals acquisition, focuses on pipeline diversification amid Keytruda’s eventual patent cliff, not absorbing Moderna’s mRNA platform. With roughly four months left in 2026 and no regulatory, financial, or competitive catalysts signaling consolidation, trader consensus at 98.9% “No” reflects the entrenched partnership model and mismatched corporate scales. Tail risks remain low but could include an unforeseen liquidity crisis at Moderna or a strategic pivot by Merck if broader mRNA economics deteriorate sharply.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于是
1% 概率
最新
最新
2026-12-31
是
1% 概率
最新
最新
2026-12-31
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.**Merck and Moderna maintain a decade-old 50/50 partnership on their personalized mRNA cancer vaccine (intismeran autogene/V940) rather than pursuing a full merger or acquisition.** Positive Phase 3 melanoma data announced in mid-August 2026, showing reduced recurrence and metastasis risk versus Keytruda alone, has driven sharp share-price gains—Moderna roughly doubling and Merck rising over 10%—while reinforcing the collaborative structure that splits costs and profits without ownership change. Merck’s recent deal activity, including the $6.7 billion Terns Pharmaceuticals acquisition, focuses on pipeline diversification amid Keytruda’s eventual patent cliff, not absorbing Moderna’s mRNA platform. With roughly four months left in 2026 and no regulatory, financial, or competitive catalysts signaling consolidation, trader consensus at 98.9% “No” reflects the entrenched partnership model and mismatched corporate scales. Tail risks remain low but could include an unforeseen liquidity crisis at Moderna or a strategic pivot by Merck if broader mRNA economics deteriorate sharply.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
市场开放时间： Aug 19, 2026, 3:58 PM ET
交易量
$425结束日期
2027-01-01市场开放时间
Aug 19, 2026, 3:58 PM ETThis market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.**Merck and Moderna maintain a decade-old 50/50 partnership on their personalized mRNA cancer vaccine (intismeran autogene/V940) rather than pursuing a full merger or acquisition.** Positive Phase 3 melanoma data announced in mid-August 2026, showing reduced recurrence and metastasis risk versus Keytruda alone, has driven sharp share-price gains—Moderna roughly doubling and Merck rising over 10%—while reinforcing the collaborative structure that splits costs and profits without ownership change. Merck’s recent deal activity, including the $6.7 billion Terns Pharmaceuticals acquisition, focuses on pipeline diversification amid Keytruda’s eventual patent cliff, not absorbing Moderna’s mRNA platform. With roughly four months left in 2026 and no regulatory, financial, or competitive catalysts signaling consolidation, trader consensus at 98.9% “No” reflects the entrenched partnership model and mismatched corporate scales. Tail risks remain low but could include an unforeseen liquidity crisis at Moderna or a strategic pivot by Merck if broader mRNA economics deteriorate sharply.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
交易量
$425结束日期
2027-01-01市场开放时间
Aug 19, 2026, 3:58 PM ET**Merck and Moderna maintain a decade-old 50/50 partnership on their personalized mRNA cancer vaccine (intismeran autogene/V940) rather than pursuing a full merger or acquisition.** Positive Phase 3 melanoma data announced in mid-August 2026, showing reduced recurrence and metastasis risk versus Keytruda alone, has driven sharp share-price gains—Moderna roughly doubling and Merck rising over 10%—while reinforcing the collaborative structure that splits costs and profits without ownership change. Merck’s recent deal activity, including the $6.7 billion Terns Pharmaceuticals acquisition, focuses on pipeline diversification amid Keytruda’s eventual patent cliff, not absorbing Moderna’s mRNA platform. With roughly four months left in 2026 and no regulatory, financial, or competitive catalysts signaling consolidation, trader consensus at 98.9% “No” reflects the entrenched partnership model and mismatched corporate scales. Tail risks remain low but could include an unforeseen liquidity crisis at Moderna or a strategic pivot by Merck if broader mRNA economics deteriorate sharply.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题